Jianfeng Chen
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Instructor, Department of Genitourinary Med Onc - Rsch, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2004 | Nanjing Medical University, CN, Environmental Medicine, Ph.D |
| 2001 | Nanjing Medical University, CN, Toxicology, M.S |
| 1998 | Nanjing Medical University, CN, Prevention Medicine, M.D |
Experience & Service
Other Professional Positions
Senior Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - 2024
Research Scientist, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2022
Research Investigator, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2020
Senior Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2014 - 2017
Research Associate, The University of Alabama at Birmingham, Birmingham, Alabama, 2006 - 2014
Assistant Professor, Nanjing Medical University, Nanjing, 2004 - 2006
Professional Memberships
Grant & Contract Support
| Date: | 2022 - 2025 |
| Title: | Development of Novel Effective Cancer Immunotherapy |
| Funding Source: | Ms. Williams TNT Fund |
| Role: | Co-I |
| Date: | 2021 - 2026 |
| Title: | Effective Combination Therapy for MTAP-deficient Bladder Carcinoma by Targeting Metabolic Vulnerability and Modulating Tumor Immune Microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA254988-01A1 |
| Date: | 2020 - 2023 |
| Title: | Investigation of Effective Therapy by Targeting the Tumor Immune Microenvironment of Fibroblast Growth Factor Receptor 3-Mutated (MFGFR3) Urothelial Carcinoma |
| Funding Source: | The David H. Koch Center for Applied Research of Genitourinary Cancers |
| Role: | Co-I |
| Date: | 2020 - 2023 |
| Title: | Broadly Applicable Cancer Immunotherapy |
| Funding Source: | The Herb Kelleher Memorial Fund |
| Role: | Key |
| Date: | 2017 - 2023 |
| Title: | Khalifa Scholar Award |
| Funding Source: | Khalifa Scholar Award |
| Role: | Co-I |
| Date: | 2017 - 2023 |
| Title: | Investigation of Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy in Urothelial Bladder Carcinoma |
| Funding Source: | Physician Scientist Award |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Huang, J, Yuan, C, Jiang, J, Chen, J, Badve, S, Gökmen-Polar, Y, Segura Lazcano, R, Yan, X, Lazar, A, Gao, J, Yao, B, Epstein, MP, Wang, L, Hu, J. Bridging cell morphological behaviors and molecular dynamics in multi-modal spatial omics with MorphLink. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40595621.
- Msaouel, P, Yu, K, Yuan, Y, Chen, J, Yan, X, Karki, M, Duan, F, Sheth, RA, Rao, P, Sircar, K, Shah, AY, Zurita-Saavedra, A, Genovese, G, Li, M, Yeh, CC, Dang, M, Han, G, Chu, Y, Hallin, M, Olson, P, Yang, R, Slavin, D, Der-Torossian, H, Chin, CD, Tannir, NM, Wang, L, Gao, J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 39794332.
- Coleman, K, Schroeder, A, Loth, M, Zhang, D, Park, JH, Sung, JY, Blank, N, Cowan, AJ, Qian, X, Chen, J, Jiang, J, Yan, H, Samarah, LZ, Clemenceau, JR, Jang, I, Kim, M, Barnfather, I, Rabinowitz, J, Deng, Y, Lee, EB, Lazar, A, Gao, J, Furth, EE, Hwang, TH, Wang, L, Thaiss, CA, Hu, J, Li, M. Resolving tissue complexity by multimodal spatial omics modeling with MISO. Nature Methods 22(3):530-538, 2025. e-Pub 2025. PMID: 39815104.
- Jiang, J, Liu, Y, Qin, JJ, Chen, J, Wu, J, Pizzi, M, Segura Lazcano, R, Yamashita, K, Xu, Z, Pei, G, Cho, KS, Chu, Y, Sinjab, A, Peng, F, Yan, X, Han, G, Wang, R, Dai, E, Dai, Y, Czerniak, BA, Futreal, A, Maitra, A, Lazar, A, Kadara, HN, Jazaeri, AA, Cheng, X, Ajani, JA, Gao, J, Hu, J, Wang, L. METI. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39181865.
- Maksimovic, S, Boscolo, NC, La Posta, L, Barrios, S, Moussa, MJ, Gentile, E, Pesquera, P, Li, W, Chen, J, Gomez, JA, Basi, A, Burks, JK, Alvarez-Breckenridge, C, Gao, J, Campbell, M, Dondossola, E. Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Research Communications 4(10):2621-2637, 2024. e-Pub 2024. PMID: 39248577.
- Ellis LV, Bywaters JD, Chen J. Endothelial deletion of p53 generates transitional endothelial cells and improves lung development during neonatal hyperoxia. bioRxiv, 2024. e-Pub 2024. PMID: 38766251.
- Gjuka, D, Adib, E, Garrison, K, Chen, J, Zhang, Y, Li, W, Boutz, DR, Lamb, C, Tanno, Y, Nassar, AH, El Zarif, T, Kale, N, Rakaee, M, Mouhieddine, TH, Alaiwi, SA, Gusev, A, Rogers, T, Gao, J, Georgiou, G, Kwiatkowski, DJ, Stone, E. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer cell 41(10):1774-1787.e9, 2023. e-Pub 2023. PMID: 37774699.
- Alhalabi, O, Zhu, Y, Hamza, A, Qiao, W, Lin, Y, Wang, RM, Shah, AY, Campbell, M, Holla, V, Kamat, A, Wang, WL, Wang, J, Chen, J, Meng, J, Zhang, M, Bondaruk, J, Titus, M, Genovese, G, Czerniak, BA, Shaw, KR, Meric-Bernstam, F, Guo, CC, Logothetis, CJ, Siefker-Radtke, AO, Msaouel, P, Wang, L, Liu, JY, Gao, J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
- Alhalabi, O, Chen, J, Zhang, Y, Lu, Y, Wang, Q, Ramachandran, S, Tidwell, R, Han, G, Yan, X, Meng, J, Wang, R, Hoang, A, Wang, W, Song, J, Lopez, LP, Andreev-Drakhlin, AY, Siefker-Radtke, AO, Zhang, X, Benedict, WF, Shah, AY, Wang, J, Msaouel, P, Zhang, M, Guo, CC, Czerniak, BA, Behrens, MC, Solis Soto, LM, Papadimitrakopoulou, VA, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Roth, JA, Swisher, SG, Wistuba, II, Heymach, JV, Wang, J, Campbell, M, Efstathiou, E, Titus, M, Logothetis, CJ, Ho, TH, Zhang, J, Wang, L, Gao, J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature communications 13(1), 2022. e-Pub 2022. PMID: 35379845.
- Han, G, Yang, G, Hao, D, Lu, Y, Thein, KZ, Simpson, BS, Chen, J, Sun, R, Alhalabi, O, Wang, R, Dang, M, Dai, E, Zhang, S, Nie, F, Zhao, S, Guo, CC, Hamza, A, Czerniak, BA, Cheng, C, Siefker-Radtke, AO, Bhat, KP, Futreal, A, Peng, G, Wargo, J, Peng, W, Kadara, HN, Ajani, JA, Swanton, C, Litchfield, K, Rodon Ahnert, J, Gao, J, Wang, L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34556668.
Other Articles
- Coleman, K, Schroeder, A, Loth, M, Zhang, D, Park, JH, Sung, JY, Blank, N, Cowan, AJ, Qian, X, Chen, J, Jiang, J, Yan, H, Samarah, LZ, Clemenceau, JR, Jang, I, Kim, M, Barnfather, I, Rabinowitz, J, Deng, Y, Lee, EB, Lazar, A, Gao, J, Furth, EE, Hwang, TH, Wang, L, Thaiss, CA, Hu, J, Li, M Correction to. Nature Methods 22(4):874, 2025. PMID: 40050700.
- Coleman, K, Schroeder, A, Loth, M, Zhang, D, Park, JH, Sung, JY, Blank, N, Cowan, AJ, Qian, X, Chen, J, Jiang, J, Yan, H, Samarah, LZ, Clemenceau, JR, Jang, I, Kim, M, Barnfather, I, Rabinowitz, J, Deng, Y, Lee, EB, Lazar, A, Gao, J, Furth, EE, Hwang, TH, Wang, L, Thaiss, CA, Hu, J, Li, M Author Correction. Nature Methods 22(3):635, 2025. PMID: 39856234.
Patient Reviews
CV information above last modified September 10, 2025